Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 2, 2005, Pages 319-328

  Albaaj, Fouad ^a   Hutchison, Alastair J ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Chronic renal failure; End stage renal disease; Hyperphosphataemia; Renal osteodystrophy

Indexed keywords

ALUMINUM CARBONATE; ALUMINUM DERIVATIVE; CALCIUM CARBONATE; CALCIUM DERIVATIVE; DIGOXIN; ENALAPRIL; FUROSEMIDE; LANTHANUM CARBONATE; METOPROLOL; PHENYTOIN; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D; WARFARIN;

ARTERY CALCIFICATION; BONE DISEASE; BONE TISSUE; BRONCHITIS; CALCIFICATION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY; DIARRHEA; DIET RESTRICTION; DISEASE CONTROL; DRUG ABSORPTION; DRUG BONE LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG FECES LEVEL; DRUG PENETRATION; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GRAFT OCCLUSION; HEADACHE; HEART ARRHYTHMIA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HISTOLOGY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOTENSION; KIDNEY FAILURE; METABOLIC DISORDER; MORBIDITY; MORTALITY; MUSCLE CRAMP; NAUSEA; NONHUMAN; NUTRITIONAL DISORDER; PHOSPHATE INTAKE; RENAL OSTEODYSTROPHY; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; TABLET; VOMITING;

CLINICAL TRIALS; HUMANS; KIDNEY FAILURE; LANTHANUM; PHOSPHATES; PHOSPHORUS METABOLISM DISORDERS; RENAL DIALYSIS;

EID: 14544293949     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.2.319     Document Type: Review

References (31)

1. BLOCK GA, HULBERT-SHEARON TE: Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic haemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31:607-617.
2. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphataemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis. (2000) 35:1226-1237.
3. GIACHELLI CM, SHUICHI J, SHIOI A et al.: Vascular calcification and inorganic phosphate. Am. J. Kidney Dis. (2001) 38(4 Suppl. 1):S34-S37.
4. LONDON GM, GUERIN AP, MARCHIS SJ et al.: Cardiac and arterial interactions in end-stage renal disease. Kidney Int. (1996) 50:600-608.
5. ALBAAJ F, HUTCHISON AJ: Hyperphosphataemia in renal failure: causes, consequences and current management. Drugs (2003) 63 6):577-596.
6. AMANN K, GROSS ML, LONDON GM et al.: Hyperphosphataemia - a silent killer of patients with renal failure? Nephrol. Dial. Transplant. (1999) 74:243-252.
7. ALBAAJ F, HUTCHISON AJ: Hyperphosphataemia in renal dialysis patients. Hospital pharmacy Europe (2004) 13:68-72.
8. LOWRIE EG, LEW NL: Death risk in haemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. (1990) 15:458-482.
9. The New Encyclopaedia Britannica (2003) Vol 7:152-153.
10. EVANS CH: Biochemistry of the Lanthanides. Plenum, New York, USA (1990).
11. KING RO, FRICKER SP: Rare earth phosphate binders. JMPC Monthly Report, March (1997).
12. DAMMENT SJP, WEBSTER I: Annual meeting of ASN 2003 (Abstract).
13. DRUEKE TB: Risks related to metal absorption. Proceedings of a roundtable meeting meeting held at the ASN/ISN World Nephrology Convention. Nephrol. Dial. Transplant. (2002):17.
14. Shire Pharmaceutical Development. LAM-IV-303 Study Results Meeting, Tenerife, May (2002).
15. XU J, LING E-A: Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus collosum in postnatal rat brain using electron dense tracers. J. Anat. (1994) 184:227-237.
16. HUTCHISON AJ: Lanthanum carbonate: a novel non-calcaemic phosphate binder in dialysis patients. Nephrol. Dial. Transplant. (2000) 15:113.
17. FINN WF, JOY MS, HALDICK GA: Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis. J. Am. Soc. Nephrol. (1999) 10:261 A.
18. JOY MS, FINN WF: Randomized, double-blind, placebo-controlled, dose-titration, Phase III study. A. Assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. (2003) 42:96-107.
19. HUTCHISON AJ: Improving phosphate-binder therapy as a way forward. Nephrol. Dial. Transplant. (2004) 19(Suppl. 1):i19-i24.
20. FINN WF, JOY MS, HALDICK G: Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving haemodialysis. Clin. Nephrol. (2004) 62 3):193-201.
21. European Renal Association Conference, Copenhagen, Denmark, July (2002).
22. HUTCHISON AJ, SPEAKE M, ALBAAJ F: Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol. Dial. Transplant. (2004) 19:1902-1906.
23. 40th ERA-EDTA World Congress of Nephrology, Berlin, Germany, June (2003).
24. GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. (2000) 342 20):1478-1483.
25. HSU CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am. J. Kid. Dis. (1997) 29:641-649.
26. BLOCK GA, KLASSEN PS, LAZARUS JM et al.: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15:2208-2218.
27. BEHETS SG, DAMS G, VERCAUTEREN SR et al.: Does the phosphate binder lanthanum carbonate affect bone in chronic renal failure rats? Am. J. Soc. Nephrol. (2004) 15:2219-2228.
28. D'HAESE PC, SPASOVSK GB, SIKOLE A et al.: A multicenter study on the effects of lanthanum carbonate (FosrenolR) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. (2003) 63(Suppl. 1):S73-S78.
29. DE BROE ME, D'HAESE PC: Improving outcome of hyperphosphataemia. Nephrol. Dial. Transplant. (2004) 19 Suppl. 1):i14-i18.
30. BEHETS GJ, VERBERCKMOES SC, D'HAESE PC et al.: Lanthanum carbonate: a new phosphate binder. Curr. Opin. Nephrol. Hypertens. (2004) 13(4):403-409.
31. TORRES A, DE BROE ME, D'HAESE PC, HUTCHISON AJ, JONES C: One-year, randomized, open-label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol) and calcium carbonate in dialysis patients. J. Am. Soc. Nephrol. (2003) 14:764A.